Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Astria Therapeutics Q3 EPS $(0.87) Down From $(0.61) YoY

Astria Therapeutics Q3 EPS $(0.87) Down From $(0.61) YoY

Astria Therapeutics (NASDAQ:ATXS) reported quarterly losses of $(0.87) per share. This is a 42.62 percent decrease over losses of $(0.61) per share from the same period last year.

byBenzinga Newsdesk

November 10, 2022

1 minute read

Astria Therapeutics (NASDAQ:ATXS) reported quarterly losses of $(0.87) per share. This is a 42.62 percent decrease over losses of $(0.61) per share from the same period last year.

Xerox Holdings Cut FY23 Revenue Guidance to $7B (Prior $7.10B) Vs. Consensus of $7.01B, Reiterated Adj Operating Margin of 5.5%-6.0%

By Benzinga Newsdesk

October 24, 6:38 AM

GUIDANCE Adjusted Operating Income and Margin FY 2023 (in millions) Profit Revenue

XRX

This Cannabis-Based Drug Has Outperformed Pfizer’s Lyrica In Clinical Trials: A New Dawn For Diabetic Nerve Pain Management?

By Javier Hasse

May 31, 2:13 PM

Zelira Therapeutics Ltd (ASX: ZLD) (OTCQB: ZLDAF), a leading player in cannabinoid medicine research, has successfully demonstrated that its proprietary drug for diabetic nerve pain, ZLT-L-007, surpasses the efficacy of Pfizer Inc. (NYSE:

PFE